Erasca

Erasca is a clinical-stage precision oncology company with a mission to eradicate cancer. The company's primary focus is on shutting down the RAS/MAPK pathway, a commonly mutated signaling cascade in cancer that affects approximately 5.5 million lives globally each year. By targeting this pathway, Erasca aims to make a significant difference in the treatment of various devastating cancers.

The company's business model revolves around the development and commercialization of a robust pipeline of therapeutic programs. These programs are designed to comprehensively shut down the RAS/MAPK pathway, regardless of the modality. This approach could potentially transform the lives of millions of cancer patients, offering them hope for a brighter, cancer-free future.

Erasca was co-founded in July 2018 by Jonathan Lim, a physician-turned-venturepreneur. Jonathan has a track record of founding, funding, and leading biotechnology companies that have achieved global regulatory approval and launched several therapeutic products in oncology, immunology, and drug delivery. These products have benefitted thousands of patients worldwide and generated approximately $10 billion of shareholder value.

Erasca operates in the global oncology market, serving a wide range of clients, including healthcare providers and cancer patients. The company generates revenue through the development, approval, and commercialization of its therapeutic products.

Keywords: Erasca, Oncology, Cancer, RAS/MAPK Pathway, Therapeutic Programs, Clinical-stage, Precision Oncology, Biotechnology, Healthcare, Drug Development.